Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Tour de France winner Riis knew his team was doping, probe says

Published 06/23/2015, 09:33 AM
Updated 06/23/2015, 09:34 AM
© Reuters. Saxo Bank cycling team director Riis looks on during a news conference in Madrid

COPENHAGEN (Reuters) - Former Tour de France winner Bjarne Riis failed to act after learning that riders on the professional cycling team he managed were using performance-enhancing drugs, a damning report from Danish sporting authorities said.

The report into claims of doping in Danish cycling was released on Tuesday by the country's Anti-Doping Authority and National Olympic Committee after a two-and-a-half year investigation that collated material from more than 50 interviews.

It followed a similar U.S. probe that ended with Lance Armstrong, hitherto the sport's global icon, being stripped of his seven Tour De France titles for doping offences and banned from professional cycling for life.

Riis, 51, won the Tour in 1996 and was feted during his heyday as the greatest Danish cyclist of the modern era, but he subsequently admitted having doped during his career.

He later managed Team Saxo, which competes on the main pro circuit, before being sacked by the rebranded Team Tinkoff-Saxo in March following a dispute with new owner Oleg Tinkov.

"Management, with Bjarne Riis in overall charge, has at a minimum had knowledge of doping within the team, but failed to intervene. It is completely unacceptable," Danish Anti-Doping Authority director Michael Ash said in a statement on Tuesday.

Armstrong's dramatic fall from grace in 2012 lifted the lid on a hitherto largely hidden culture of drug use within the sport from which Danish racing was not immune.

Morten Molholm Hansen, director of the Sports Federation of Denmark, on Tuesday criticized the "tradition of performance-enhancing drugs in cycling, which leads to a mentality that (such behavior) is acceptable."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"Danish leaders in the sport failed to respond to specific knowledge about their own riders' use of doping," the Authority added in a statement.

Tuesday's report recommended that night-time testing of athletes should be introduced, that blood values from tests should either be delayed or not revealed to them and that a licensing system for team managers and doctors be introduced.

It also contained an allegation by Danish rider Bo Hamburger that Riis asked him in 2000 to acquire EPO, which improves aerobic capacity by artificially raising the user's red blood cell count, for German Team Telekom rider Jorg Jaksche.

Jaksche confirmed the story to investigators, but Riis rejected the allegation.

With many revelations contained in the report dating back more than eight years, a statue of limitations for doping cases applies and no disciplinary charges can be brought.

Riis and Team Tinkoff-Saxo's main sponsors, Tinkoff Bank and Saxo Bank, were not immediately available for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.